Experienced in Hydatidiform Mole

Dr. Robert M. Wenham

Gynecologic Oncology | Obstetrics and Gynecology | Oncology
H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc
12902 Usf Magnolia Dr, 
Tampa, FL 
Accepting New Patients
Offers Telehealth
Experienced in Hydatidiform Mole
H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc
12902 Usf Magnolia Dr, 
Tampa, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Wenham is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Tampa, Florida. Dr. Wenham is rated as an Experienced provider by MediFind in the treatment of Hydatidiform Mole. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Salpingo-Oophorectomy, and Oophorectomy. Dr. Wenham is currently accepting new patients.

His clinical research consists of co-authoring 105 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Obstetrics and Gynecology
Oncology
Licenses
Obstetrics & Gynecology in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

H LEE MOFFITT CANCER CTR AND RES INST LIFE TIME CANCER SCRN CTR INC
12902 Usf Magnolia Dr, Tampa, FL 33612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Cediranib maleate, Olaparib
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Other, Biological
Study Drug: Vigil
Study Phase: Phase 2
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Enrollment Status: Terminated
Publish Date: March 24, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Prospective Study of Quality of Life in Patients Undergoing Pelvic Exenteration
A Prospective Study of Quality of Life in Patients Undergoing Pelvic Exenteration
Enrollment Status: Completed
Publish Date: December 18, 2024
Intervention Type: Behavioral
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
Enrollment Status: Completed
Publish Date: January 10, 2024
Intervention Type: Drug
Study Drugs: Entinostat, Avelumab
Study Phase: Phase 1/Phase 2
Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer: Prospective Study of Pharmacokinetics Patterns and Underlying Biology
Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer: Prospective Study of Pharmacokinetics Patterns and Underlying Biology
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Procedure
A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy
A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy
Enrollment Status: Terminated
Publish Date: December 15, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 2
Feasibility Study for Electroacupuncture for Chemotherapy- Induced Peripheral Neuropathy (CIPN) Using a Point-Of-Nerve Conduction Device (NeuroMetrix) and the Rydel-Seiffer Tuning Fork
Feasibility Study for Electroacupuncture for Chemotherapy- Induced Peripheral Neuropathy (CIPN) Using a Point-Of-Nerve Conduction Device (NeuroMetrix) and the Rydel-Seiffer Tuning Fork
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Device
Study Phase: Not Applicable
Phase 2 Trial of Dose Dense (Weekly) Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer
Phase 2 Trial of Dose Dense (Weekly) Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drugs: Pembrolizumab, Paclitaxel
Study Phase: Phase 2
Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy
Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy
Enrollment Status: Terminated
Publish Date: June 14, 2022
Intervention Type: Biological, Procedure
Study Phase: Early Phase 1
A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Procedure, Device, Drug
Study Phase: Phase 3
A Phase IA/IB Trial of PTX-200 and Carboplatin in Patients With Platinum-Resistant Recurrent Ovarian Cancer
A Phase IA/IB Trial of PTX-200 and Carboplatin in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Enrollment Status: Terminated
Publish Date: September 24, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Pilot Randomized, Placebo-Controlled, Trial of Fermented Wheat Germ Extract in Women With Ovarian Cancer
A Pilot Randomized, Placebo-Controlled, Trial of Fermented Wheat Germ Extract in Women With Ovarian Cancer
Enrollment Status: Terminated
Publish Date: January 23, 2019
Intervention Type: Drug, Other
Study Phase: Early Phase 1
View 12 Less Clinical Trials

105 Total Publications

Adnexal mass management by minimally invasive surgery at a comprehensive cancer center.
Adnexal mass management by minimally invasive surgery at a comprehensive cancer center.
Journal: Journal of robotic surgery
Published: September 12, 2025
Similar Doctors
Advanced in Hydatidiform Mole
Dr. Monica Avila
Gynecologic Oncology | Oncology
Advanced in Hydatidiform Mole
Dr. Monica Avila
Gynecologic Oncology | Oncology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-860-2778
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Monica Avila is a Gynecologic Oncologist and an Oncologist in Tampa, Florida. Dr. Avila is rated as an Advanced provider by MediFind in the treatment of Hydatidiform Mole. Her top areas of expertise are Malignant Mixed Mullerian Tumor, Pseudomyxoma Peritonei, Testicular Yolk Sac Tumor, Oophorectomy, and Bladder Reconstruction. Dr. Avila is currently accepting new patients.

Advanced in Hydatidiform Mole
Dr. Hye S. Chon
Gynecologic Oncology | Obstetrics and Gynecology
Advanced in Hydatidiform Mole
Dr. Hye S. Chon
Gynecologic Oncology | Obstetrics and Gynecology

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-860-2778
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hye Chon is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Tampa, Florida. Dr. Chon is rated as a Distinguished provider by MediFind in the treatment of Hydatidiform Mole. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Bladder Reconstruction, and Hysterectomy. Dr. Chon is currently accepting new patients.

Advanced in Hydatidiform Mole
Dr. Matthew L. Anderson
Obstetrics and Gynecology | Gynecologic Oncology
Advanced in Hydatidiform Mole
Dr. Matthew L. Anderson
Obstetrics and Gynecology | Gynecologic Oncology

Tampa General Medical Group Inc

1 Tampa General Cir, 
Tampa, FL 
 (9.0 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Anderson is an Obstetrics and Gynecologist and a Gynecologic Oncologist in Tampa, Florida. Dr. Anderson is rated as a Distinguished provider by MediFind in the treatment of Hydatidiform Mole. His top areas of expertise are Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Hysterectomy, and Oophorectomy. Dr. Anderson is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wenham's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 8 Advanced Conditions
View All 47 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile